



## Abstract SA-β-galactosidase activity in effector and regulatory T cells <sup>+</sup>

Kseniia Matveeva<sup>1,\*</sup>, Daniil Shevyrev<sup>1</sup>

- <sup>1</sup> Sirius University of Science and Technology, Sirius, 354340 Sochi, Russia
- \* Correspondence: matveeva.ks@learn.siriusuniversity.ru (K.M.)
- + Presented at the title, place, and date.

**Abstract:** The aging of the immune system is accompanied by a significant increase in the risk of developing age-related pathologies, including inflammatory, autoimmune diseases and oncology. Age-dependent decline in immune function is accompanied by a gradual accumulation of senescent (aged) cells that are the source of chronic inflammation. The main producers of proinflammatory cytokines in the body are activated effector T cells. With age, along with an increase in chronic inflammation (InflammAging), the ability of the immune system to suppress and/or remove activated and senescent effector cells decreases. With age, there is also a decrease in the function of CD3<sup>+</sup>CD4<sup>+</sup>CD25<sup>hi</sup>CD127<sup>lo/-</sup> T-regulatory cells (Treg), which unbalances the immune system and increases the risk of autoimmune pathologies.

In *ex vivo* analysis, senescence status of activated (CD25<sup>+</sup> and HLA-DR<sup>+</sup>) and non-activated (CD25<sup>-</sup> and HLA-DR<sup>-</sup>) CD4<sup>+</sup> and CD8<sup>+</sup> T cells, as well as Tregs with phenotypes CD3<sup>+</sup>CD4<sup>+</sup>CD25<sup>hi</sup>CD127<sup>lo/-</sup> and CD3<sup>+</sup>CD8<sup>+</sup>CD127<sup>lo/-</sup>HLA-DR<sup>+</sup> (CD4<sup>+</sup>Treg and CD8<sup>+</sup>Treg respectively) were assessed by using SA- $\beta$ -galactosidase activity assay.

Among donors in activated (CD25<sup>+</sup> and HLA-DR<sup>+</sup>) both CD4<sup>+</sup> and CD8<sup>+</sup> lymphocytes, SA- $\beta$ -Gal activity was higher compared to non-activated lymphocytes. Whereas, SA- $\beta$ -Gal activity was lowest in Tregs, suggesting their specific metabolic patterns. There were no significant differences between the populations of CD3<sup>+</sup>CD4<sup>+</sup> and CD3<sup>+</sup>CD8<sup>+</sup> lymphocytes in SA- $\beta$ -Gal activity. Thus, the activity of SA- $\beta$ -Gal marker of senescent and activated effector T cells can be used to analyze the aging of the immune system in further functional tests.

Using this approach, the phenotypic features and functional activity of senescent T cells among young (< 30 years old) and older (> 60 years old) donors will be studied in detail. The development of this model in non-human primates of different age groups will facilitate future preclinical trials for senolytic and senomorphic drugs, and substances that enhance the repair of double-strand breaks.

Keywords: SA-β-Gal; senescence; lymphocytes; regulatory T cells; Treg.

## Supplementary Materials:

**Author Contributions:** Conceptualization, D.S..; methodology, K.M., D.S.; validation, D.S.; formal analysis, K.M., D.S.; investigation, K.M., D.S.; resources, D.S.; data curation, K.M.; writing—original draft preparation, K.M.; writing—review and editing, D.S.; visualization, K.M.; supervision, D.S.; project administration, D.S.; funding acquisition, D.S. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by Russian Science Foundation, grant number 23-15-00443.

**Citation:** Matveeva, K.; Shevyrev, D. SA-β-galactosidase activity in effector and regulatory T cells. *Med. Sci. Forum* **2023**, *2*, x. https://doi.org/10.3390/xxxxx

Academic Editor: Firstname Lastname

Published: date

**Publisher's Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



**Copyright:** © 2023 by the authors. Submitted for possible open access publication under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/license s/by/4.0/). **Institutional Review Board Statement:** The study was conducted in accordance with the Declaration of Helsinki, and approved by the local ethics committee of Sirius University (date of approval: 2023-03-06).

**Informed Consent Statement:** Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: Data is contained within the article or supplementary material.

**Acknowledgments:** We are sincerely grateful to Stanislav Rybtsov for helpful comments and proofreading of the manuscript, as well as the staff of the Cell Technology and Immunology Resource Center of Sirius University for providing equipment and assistance in performing experiments.

**Conflicts of Interest:** The authors declare no potential conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.